Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Accured Expenses (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Change in Accured Expenses data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 89.19% year-over-year to $1.3 million; the TTM value through Dec 2025 reached -$8.1 million, down 105.4%, while the annual FY2025 figure was -$8.1 million, 105.4% down from the prior year.
  • Change in Accured Expenses reached $1.3 million in Q4 2025 per ACRS's latest filing, down from $1.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $11.6 million in Q4 2024 and bottomed at -$12.9 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $50700.0, with a median of $657500.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: surged 928.49% in 2023, then crashed 1012.67% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.5 million in 2021, then crashed by 126.81% to -$681000.0 in 2022, then soared by 928.49% to $5.6 million in 2023, then soared by 105.1% to $11.6 million in 2024, then tumbled by 89.19% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $1.3 million in Q4 2025, $1.3 million in Q3 2025, and $399000.0 in Q2 2025.